Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Brain Canada | OTHER |
| Heart and Stroke Foundation of Canada | OTHER |
| Canadian Stroke Consortium (CSC) | OTHER |
Not provided
Not provided
Not provided
Not provided
The INCOGNITO Pilot Trial is a single centre pilot prospective randomized open-label blinded endpoint (PROBE) trial to assess the feasibility of a full-scale randomized trial to determine whether an occult cancer screening strategy of FDG PET/CT (F-fluorodeoxyglucose positron emission/computed tomography) in addition to usual care increases the number of occult cancers diagnosed after screening compared to usual care cancer screening alone in patients with cryptogenic stroke.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Intensive Cancer Screening | Experimental | Usual care plus FDG PET/CT |
|
| Usual Care | Other | Cancer screening according to sex, age and risk as per Canadian Task Force on Preventative Health Care) |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| FDG PET/CT | Diagnostic Test | F-fluorodeoxyglucose positron emission/computed tomography |
|
| Measure | Description | Time Frame |
|---|---|---|
| Participant Recruitment | Number of participants recruited | Over 12 months |
| Measure | Description | Time Frame |
|---|---|---|
| Eligibility Rate | percentage of screened patients who are eligible | Over 12 months |
| Consent Rate | percentage of eligible patients who provide consent |
| Measure | Description | Time Frame |
|---|---|---|
| Screening time frame | time from diagnosis to screening | Over 24 months |
| Reasons for participation | Reasons for accepting/declining participation |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Dariush Dowlatshahi, MD PhD | Contact | 613-798-5555 | 14709 | ddowlat@toh.ca |
| Deborah Siegal, MD | Contact | 613-737-8899 | 78060 | dsiegal@toh.ca |
| Name | Affiliation | Role |
|---|---|---|
| Dariush Dowlatshahi, MD PhD | Ottawa Hospital Research Institute | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| The Ottawa Hospital | Recruiting | Ottawa | Ontario | K1Y 4E9 | Canada |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D000083242 | Ischemic Stroke |
| ID | Term |
|---|---|
| D020521 | Stroke |
| D002561 | Cerebrovascular Disorders |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Usual Care | Diagnostic Test | Cancer screening according to sex, age and risk as per Canadian Task Force on Preventative Health Care |
|
| Over 12 months |
| Retention Rate | percentage of participants retained at follow-up | Over 24 months |
| Study Completion Rate | percentage of participants who completed all study procedures | Over 24 months |
| Adherence Rate | adherence to screening strategy | Over 24 months |
| Over 24 months |
| Usual care cancer screening strategies | Usual care cancer screening strategies ordered by treating physicians | Over 24 months |
| D009422 |
| Nervous System Diseases |
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |